South Korea
· Delayed Price · Currency is KRW HLB Therapeutics Co.,Ltd. Statistics
Total Valuation
HLB Therapeutics Co.,Ltd. has a market cap or net worth of KRW 699.99 billion. The enterprise value is 701.34 billion.
| Market Cap | 699.99B |
| Enterprise Value | 701.34B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HLB Therapeutics Co.,Ltd. has 79.82 million shares outstanding. The number of shares has increased by 10.57% in one year.
| Shares Outstanding | 79.82M |
| Shares Change (YoY) | +10.57% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 5.32% |
| Float | 69.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.73 |
| PB Ratio | 4.67 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -25.70 |
| EV / Sales | 11.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -234.98 |
Financial Position
The company has a current ratio of 3.58, with a Debt / Equity ratio of 14.47.
| Current Ratio | 3.58 |
| Quick Ratio | 2.88 |
| Debt / Equity | 14.47 |
| Debt / EBITDA | n/a |
| Debt / FCF | -8.29 |
| Interest Coverage | -6.33 |
Financial Efficiency
Return on equity (ROE) is -15.72% and return on invested capital (ROIC) is -3.30%.
| Return on Equity (ROE) | -15.72% |
| Return on Assets (ROA) | -3.11% |
| Return on Capital (ROIC) | -3.30% |
| Revenue Per Employee | 615.29M |
| Profits Per Employee | -278.45M |
| Employee Count | 98 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 9.65 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +139.50% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +139.50% |
| 50-Day Moving Average | 8,896.00 |
| 200-Day Moving Average | 8,026.72 |
| Relative Strength Index (RSI) | 48.72 |
| Average Volume (20 Days) | 618,067 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HLB Therapeutics Co.,Ltd. had revenue of KRW 60.30 billion and -27.29 billion in losses. Loss per share was -369.96.
| Revenue | 60.30B |
| Gross Profit | 8.20B |
| Operating Income | -10.51B |
| Pretax Income | -27.37B |
| Net Income | -27.29B |
| EBITDA | -2.20B |
| EBIT | -10.51B |
| Loss Per Share | -369.96 |
Balance Sheet
The company has 46.40 billion in cash and 24.76 billion in debt, giving a net cash position of 21.65 billion or 271.20 per share.
| Cash & Cash Equivalents | 46.40B |
| Total Debt | 24.76B |
| Net Cash | 21.65B |
| Net Cash Per Share | 271.20 |
| Equity (Book Value) | 171.13B |
| Book Value Per Share | 1,877.20 |
| Working Capital | 48.23B |
Cash Flow
In the last 12 months, operating cash flow was -2.67 billion and capital expenditures -312.07 million, giving a free cash flow of -2.98 billion.
| Operating Cash Flow | -2.67B |
| Capital Expenditures | -312.07M |
| Free Cash Flow | -2.98B |
| FCF Per Share | -37.39 |
Margins
Gross margin is 13.60%, with operating and profit margins of -17.42% and -45.25%.
| Gross Margin | 13.60% |
| Operating Margin | -17.42% |
| Pretax Margin | -45.40% |
| Profit Margin | -45.25% |
| EBITDA Margin | -3.64% |
| EBIT Margin | -17.42% |
| FCF Margin | -4.95% |
Dividends & Yields
HLB Therapeutics Co.,Ltd. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.57% |
| Shareholder Yield | -10.57% |
| Earnings Yield | -4.22% |
| FCF Yield | -0.43% |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.035.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.035 |